Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injectable triptorelin added to ongoing treatment for obsessive-compulsive disorder
IRCT20180309039012N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Apr 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, double-blind trial of triptorelin in obsessive compulsive disorder (OCD) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Effectiveness of adjunctive triptorelin on obsessive symptoms and impairment. Started Apr 2018; status: completed.
02
Drugs
triptorelin
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20180309039012N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180309039012N1.